Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Jun
17
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
Jun
04
Supporting Families During Dravet Syndrome Awareness Month: A look into Camp Small Steps
Jun
03
Running Toward Relief: How Cassie is Reclaiming Her Life With Psoriatic Arthritis
Jun
01
UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members
May
19
BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
May
14
UCB Issues Voluntary Recall of Select Lots of CIMZIA® Pre-Filled Syringes (PFS) in the United States
May
04
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
Apr
17
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
Apr
15
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting